Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/j.ajkd.2012.08.010 | DOI Listing |
BMC Med
August 2024
Donal O'Donoghue Renal Research Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
Blood Purif
January 2022
Oswaldo Ramos Foundation-Hrim, Federal University of São Paulo, São Paulo, Brazil.
Over the last 2 decades, there has been a great accumulation of new evidence regarding the management of nutritional and metabolic aspects of kidney disease. The 2020 update to the KDOQI Clinical Practice Guideline for Nutrition in CKD provides a comprehensive up-to-date information on the understanding and care of patients with CKD. It provides updated information on nutritional aspects of kidney disease for the practicing clinician and allied health-care workers.
View Article and Find Full Text PDFAm J Kidney Dis
May 2020
Keck School of Medicine, University of Southern California, Los Angeles, CA.
The first KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection was published in 2008. The ensuing decade bore witness to remarkable advances in the treatment of HCV infection following the approval of direct-acting antiviral (DAA) agents that deliver cure rates routinely >95%. In this context, the KDIGO organization correctly recognized the need for an updated HCV guideline that would be relevant to the treatment of HCV-infected patients with kidney disease in the DAA era.
View Article and Find Full Text PDFAm J Kidney Dis
March 2020
Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Living kidney donation is widely practiced throughout the world. During the past 2 decades, various groups have provided guidance about the evaluation and care of living donors. However, during this time, our knowledge in the field has advanced substantially and many agreed on the need for a comprehensive, unifying document.
View Article and Find Full Text PDFAm J Kidney Dis
April 2019
Department of Medicine, University of Utah, Salt Lake City, UT.
Hypertension is a modifiable risk factor for cardiovascular morbidity and mortality and reduction of elevated blood pressure (BP) remains an important intervention for slowing kidney disease progression. Over the past decade, the most appropriate BP target for initiation and titration of BP-lowering medications has been an area of intense research and debate within the clinical community. In 2017, the American College of Cardiology and the American Heart Association (ACC/AHA) in conjunction with several other professional societies released new hypertension guidelines based on data from a systematic review of clinical trials and observational data.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!